Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hyperuricemia 1Fallopian Tube Neoplasms 1Congenital Abnormalities 1Carcinoma, Ovarian Epithelial 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × Allopurinol × Clear all
NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
14 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡